Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States

2008 ◽  
Vol 26 (4) ◽  
pp. 612-619 ◽  
Author(s):  
Anil K. Chaturvedi ◽  
Eric A. Engels ◽  
William F. Anderson ◽  
Maura L. Gillison
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Squamous Cell ◽  
The United States ◽  
Squamous Cell Carcinomas ◽  
Anatomic Site ◽  
Absolute Increase ◽  
Oral Squamous Cell Carcinomas ◽  
Incidence Trends ◽  
The Impact

Purpose To investigate the impact of human papillomavirus (HPV) on the epidemiology of oral squamous cell carcinomas (OSCCs) in the United States, we assessed differences in patient characteristics, incidence, and survival between potentially HPV-related and HPV-unrelated OSCC sites. Patients and Methods Data from nine Surveillance, Epidemiology, and End Results program registries (1973 to 2004) were used to classify OSCCs by anatomic site as potentially HPV-related (n = 17,625) or HPV-unrelated (n = 28,144). Joinpoint regression and age-period-cohort models were used to assess incidence trends. Life-table analyses were used to compare 2-year overall survival for HPV-related and HPV-unrelated OSCCs. Results HPV-related OSCCs were diagnosed at younger ages than HPV-unrelated OSCCs (mean ages at diagnosis, 61.0 and 63.8 years, respectively; P < .001). Incidence increased significantly for HPV-related OSCC from 1973 to 2004 (annual percentage change [APC] = 0.80; P < .001), particularly among white men and at younger ages. By contrast, incidence for HPV-unrelated OSCC was stable through 1982 (APC = 0.82; P = .186) and declined significantly during 1983 to 2004 (APC = −1.85; P < .001). When treated with radiation, improvements in 2-year survival across calendar periods were more pronounced for HPV-related OSCCs (absolute increase in survival from 1973 through 1982 to 1993 through 2004 for localized, regional, and distant stages = 9.9%, 23.1%, and 18.6%, respectively) than HPV-unrelated OSCCs (5.6%, 3.1%, and 9.9%, respectively). During 1993 to 2004, for all stages treated with radiation, patients with HPV-related OSCCs had significantly higher survival rates than those with HPV-unrelated OSCCs. Conclusion The proportion of OSCCs that are potentially HPV-related increased in the United States from 1973 to 2004, perhaps as a result of changing sexual behaviors. Recent improvements in survival with radiotherapy may be due in part to a shift in the etiology of OSCCs.

The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States

2011 ◽  
Vol 142 (8) ◽  
pp. 915-924 ◽  
Author(s):  
Jennifer L. Cleveland ◽  
Michele L. Junger ◽  
Mona Saraiya ◽  
Lauri E. Markowitz ◽  
Eileen F. Dunne ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Squamous Cell ◽  
The United States ◽  
Squamous Cell Carcinomas

scholarly journals Time‐varying survival effects for squamous cell carcinomas at oropharyngeal and nonoropharyngeal head and neck sites in the United States, 1973‐2015

Cancer ◽  
2020 ◽  
Vol 126 (23) ◽  
pp. 5137-5146
Author(s):  
Andrew F. Brouwer ◽  
Kevin He ◽  
Steven B. Chinn ◽  
Alison M. Mondul ◽  
Christina H. Chapman ◽  
...  
Keyword(s):  
United States ◽  
Head And Neck ◽  
Squamous Cell ◽  
The United States ◽  
Squamous Cell Carcinomas ◽  
Time Varying

Incidence trends for human papillomavirus-related (HPV-R) and unrelated (HPV-U) head and neck squamous cell carcinomas (HNSCC) in the United States (US)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6001-6001 ◽  
Author(s):  
A. Chaturvedi ◽  
E. Engels ◽  
W. Anderson ◽  
M. Gillison
Keyword(s):  
The United States ◽  
Underlying Disease ◽  
Birth Cohorts ◽  
Anatomic Site ◽  
Annual Percent Change ◽  
Absolute Increase ◽  
Incidence Trends ◽  
The Us ◽  
Smoking Behaviors ◽  
Regional Disease

6001 Background: HNSCC are etiologically heterogeneous, with one subset primarily attributable to HPV and another to tobacco and alcohol. Methods: Data from SEER9 program registries were used to investigate the potential influence of HPV on incidence and survival of HNSCC in the US from 1973–2003. HNSCCs (N=58,158) were classified by anatomic site as potentially HPV-R (base of tongue; tonsil; oropharynx; N=16,712) or HPV-U (lip; tongue; gum; floor of mouth; palate; other mouth; hypopharynx; ill-defined sites of lip, oral cavity, and pharynx; N=41,446). Joinpoint regression was used to assess incidence trends and life-table methods were used to compare survival for HPV-R and HPV-U HNSCCs. Results: For HPV-R HNSCCs, age-adjusted incidence increased significantly from 1973–2003 (annual percent change [APC] = 0.65), particularly among males (APC=1.02), whites (APC=0.89), and younger ages (APCs for 30–39 = 1.46; 40- 49=1.92; 50–59=0.61, and =60= -0.66). By contrast, HPV-U HNSCC incidence was stable from 1973–1983 and then decreased significantly from 1983–2003 (APC= -2.42). Mean age at diagnosis was younger for HPV-R HNSCC than HPV-U (61.1 vs. 64.5 years; p<0.001), and from 1973- 2003, decreased significantly for HPV-R, but increased for HPV-U. Improvements in overall survival (OS) were observed for HPV-R (all stages) and HPV-U (regional and distant) HNSCC treated by radiotherapy (RT) from 1973–2003, but were more marked for HPV-R HNSCC, e.g. absolute increase in two-year OS for regional disease of 24.4% (vs. 5.8% for HPV-U). OS for HPV-R (local and regional) was significantly better than HPV-U HNSCC if treated by RT, but worse if not so treated. Conclusions: The proportion of HNSCC that is potentially HPV- R increased in the US from 1973–2003, particularly among recent birth cohorts, perhaps due to changing sexual and smoking behaviors. Recent improvements in locoregional control with RT-based therapy may be due in part to a gradual shift in the etiology of the underlying disease. No significant financial relationships to disclose.

scholarly journals Differences in Sociodemographic Correlates of Human Papillomavirus-Associated Cancer Survival in the United States

2021 ◽  
Vol 28 ◽  
pp. 107327482110418
Author(s):  
Nosayaba Osazuwa-Peters ◽  
Matthew C. Simpson ◽  
Rebecca L. Rohde ◽  
Sai D Challapalli ◽  
Sean T. Massa ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Cervical Carcinoma ◽  
Cancer Survival ◽  
The United States ◽  
Vaccine Uptake ◽  
Anatomic Site ◽  
Specific Patient ◽  
Clinical Variables ◽  
Risk Of Death

Objectives Human papillomavirus (HPV)-associated cancers account for about 9% of the cancer mortality burden in the United States; however, survival differs among sociodemographic factors. We determine sociodemographic and clinical variables associated with HPV-associated cancer survival. Methods Data derived from the Surveillance, Epidemiology, and End Results 18 cancer registry were analyzed for a cohort of adult patients diagnosed with a first primary HPV-associated cancer (anal, cervical, oropharyngeal, penile, vaginal, and vulvar cancers), between 2007 and 2015. Multivariable Fine and Gray proportional hazards regression models stratified by anatomic site estimated the association of sociodemographic and clinical variables and cancer-specific survival. Results A total of 77 774 adults were included (11 216 anal, 27 098 cervical, 30 451 oropharyngeal, 2221 penile, 1176 vaginal, 5612 vulvar; average age = 57.2 years). The most common HPV-associated cancer was cervical carcinoma (58%) for females and oropharyngeal (81%) for male. Among patients diagnosed with anal/rectal squamous cell carcinoma (SCC), males had a higher risk of death than females. NonHispanic (NH) blacks had a higher risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma; and Hispanics had a higher risk of death from oropharyngeal SCC than NH whites. Marital status was associated with risk of death for all anatomic sites except vulvar. Compared to nonMedicaid insurance, patients with Medicaid and uninsured had higher risk of death from anal/rectal SCC, oropharyngeal SCC, and cervical carcinoma. Conclusions There exists gender (anal) and racial and insurance (anal, cervical, and oropharyngeal) disparities in relative survival. Concerted efforts are needed to increase and sustain progress made in HPV vaccine uptake among these specific patient subgroups, to reduce cancer incidence.

Sign in / Sign up

Export Citation Format

Share Document